The addition of Tecentriq (atezolizumab) to first-line treatment with Avastin (bevacizumab) and chemotherapy does not significantly extend survival without disease worsening in people with newly-diagnosed advanced ovarian cancer, a recent trial shows. While the IMagyn050 Phase 3 trial (NCT03038100) failed to meet one of its primary endpoints, researchers are gathering more data to determine whether the Tecentriq combo increases survival times, either in the overall trial population or in a subgroup whose cancers are positive…
You must be logged in to read/download the full post.
The post Tecentriq Combo Produces Disappointing Results in Advanced Ovarian Cancer Trial appeared first on BioNewsFeeds.